• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Pre-perimetric glaucoma: To treat or not to treat?


The answer to the question of whether it is necessary to diagnose and treat pre-perimetric glaucoma is not a simple "yes" or "no."

The answer to the question of whether it is necessary to diagnose and treat pre-perimetric glaucoma (PPG) is not a simple "yes" or "no," according to David S. Greenfield, MD, and Kuldev Singh, MD, MPH.

In deciding the approach to management of PPG, Dr. Greenfield advocated applying the "Principle of the 3 Rs" that considers: 1) eyes with PPG are likely at greater Risk for developing progressive visual field changes, 2) the need to measure the Rate of change, and 3) the need to Re-evaluate these eyes constantly for risk factors associated with progression.

"However, there is also a role for observation in eyes with minimal risk of loss in vision-related quality of life, a slow velocity of change, or patients with reduced life expectancy," Dr. Greenfield added.

Evidence in favor of treatment

One of the limitations in guiding therapeutic decisions for PPG is that there are no randomized controlled trials that specifically enrolled patients with PPG. However, it can be assumed that a subset of patients in the Ocular Hypertension Treatment Study (OHTS) had undetected PPG, and in the Diagnostic Innovations in Glaucoma Study (DIGS), there was a subset of patients with baseline retinal nerve fiber layer (RNFL) atrophy. Data available from these cohorts indicate they have a greater risk of disease progression than their counterparts without evidence of structural abnormality, Dr. Greenfield said.

In DIGS, patients with suspected glaucoma with baseline RNFL atrophy had a four-fold increased risk of developing perimetric disease during follow-up, and those whose optic nerves showed glaucomatous progression over time had a 26-fold increased risk of developing visual field loss.

"Imaging plays a critical role for assessing the risk of visual field loss in eyes with PPG," Dr. Greenfield said. "Development of a visual field defect can often be predicted by identifying eyes with an abnormally thin retinal nerve fiber layer thickness using either scanning laser polarimetry or time-domain OCT, according to findings from the DIGS study."

Data from the Confocal Scanning Laser Ophthalmoscopy (CSLO) ancillary study of OHTS showed the risk for developing abnormal visual fields was increased nine-fold in eyes with abnormal baseline optic disc topography. Furthermore, in OHTS, two of the five originally described risk factors for converting to glaucoma, increased cup-disc ratio and visual field pattern standard deviation, are surrogates of PPG, Dr. Greenfield said.

© 2024 MJH Life Sciences

All rights reserved.